Long-Term Disease Control of a Non-Operable Neuroendocrine Tumor of the Lung with Lanreotide: A Case Study

Bronchopulmonary neuroendocrine tumors (NETs) are malignant tumors that represent approximately 20% of all lung cancers. The therapeutic option for advanced or metastatic bronchopulmonary NETs is mainly palliation of symptoms; options need to be individualized and, therefore, rely on the knowledge o...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Fraeyenhove, F., De Droogh, E., Meireson, N., Galdermans, D., Goor, C., Van Acker, F., Mattelaer, C., De Ruyter, V., Schrijvers, D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2012
Materias:
Published online: December, 2012
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551439/
https://www.ncbi.nlm.nih.gov/pubmed/23341808
http://dx.doi.org/10.1159/000345695
_version_ 1782256561830232064
author Van Fraeyenhove, F.
De Droogh, E.
Meireson, N.
Galdermans, D.
Goor, C.
Van Acker, F.
Mattelaer, C.
De Ruyter, V.
Schrijvers, D.
author_facet Van Fraeyenhove, F.
De Droogh, E.
Meireson, N.
Galdermans, D.
Goor, C.
Van Acker, F.
Mattelaer, C.
De Ruyter, V.
Schrijvers, D.
author_sort Van Fraeyenhove, F.
collection PubMed
description Bronchopulmonary neuroendocrine tumors (NETs) are malignant tumors that represent approximately 20% of all lung cancers. The therapeutic option for advanced or metastatic bronchopulmonary NETs is mainly palliation of symptoms; options need to be individualized and, therefore, rely on the knowledge of multidisciplinary teams. Somatostatin analogs have been widely used in NETs for control of hormonal syndromes and are currently under evaluation for their antiproliferative activity. Here, we present a case of NET of the lung, for which we achieved long-term disease control with a treatment comprising the somatostatin analog lanreotide Autogel(®) in a patient with limited therapeutic options due to considerable comorbidity, while preserving his quality of life.
format Online
Article
Text
id pubmed-3551439
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-35514392013-01-22 Long-Term Disease Control of a Non-Operable Neuroendocrine Tumor of the Lung with Lanreotide: A Case Study Van Fraeyenhove, F. De Droogh, E. Meireson, N. Galdermans, D. Goor, C. Van Acker, F. Mattelaer, C. De Ruyter, V. Schrijvers, D. Case Rep Oncol Published online: December, 2012 Bronchopulmonary neuroendocrine tumors (NETs) are malignant tumors that represent approximately 20% of all lung cancers. The therapeutic option for advanced or metastatic bronchopulmonary NETs is mainly palliation of symptoms; options need to be individualized and, therefore, rely on the knowledge of multidisciplinary teams. Somatostatin analogs have been widely used in NETs for control of hormonal syndromes and are currently under evaluation for their antiproliferative activity. Here, we present a case of NET of the lung, for which we achieved long-term disease control with a treatment comprising the somatostatin analog lanreotide Autogel(®) in a patient with limited therapeutic options due to considerable comorbidity, while preserving his quality of life. S. Karger AG 2012-12-18 /pmc/articles/PMC3551439/ /pubmed/23341808 http://dx.doi.org/10.1159/000345695 Text en Copyright © 2012 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No-Derivative-Works License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions.
spellingShingle Published online: December, 2012
Van Fraeyenhove, F.
De Droogh, E.
Meireson, N.
Galdermans, D.
Goor, C.
Van Acker, F.
Mattelaer, C.
De Ruyter, V.
Schrijvers, D.
Long-Term Disease Control of a Non-Operable Neuroendocrine Tumor of the Lung with Lanreotide: A Case Study
title Long-Term Disease Control of a Non-Operable Neuroendocrine Tumor of the Lung with Lanreotide: A Case Study
title_full Long-Term Disease Control of a Non-Operable Neuroendocrine Tumor of the Lung with Lanreotide: A Case Study
title_fullStr Long-Term Disease Control of a Non-Operable Neuroendocrine Tumor of the Lung with Lanreotide: A Case Study
title_full_unstemmed Long-Term Disease Control of a Non-Operable Neuroendocrine Tumor of the Lung with Lanreotide: A Case Study
title_short Long-Term Disease Control of a Non-Operable Neuroendocrine Tumor of the Lung with Lanreotide: A Case Study
title_sort long-term disease control of a non-operable neuroendocrine tumor of the lung with lanreotide: a case study
topic Published online: December, 2012
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551439/
https://www.ncbi.nlm.nih.gov/pubmed/23341808
http://dx.doi.org/10.1159/000345695
work_keys_str_mv AT vanfraeyenhovef longtermdiseasecontrolofanonoperableneuroendocrinetumorofthelungwithlanreotideacasestudy
AT dedrooghe longtermdiseasecontrolofanonoperableneuroendocrinetumorofthelungwithlanreotideacasestudy
AT meiresonn longtermdiseasecontrolofanonoperableneuroendocrinetumorofthelungwithlanreotideacasestudy
AT galdermansd longtermdiseasecontrolofanonoperableneuroendocrinetumorofthelungwithlanreotideacasestudy
AT goorc longtermdiseasecontrolofanonoperableneuroendocrinetumorofthelungwithlanreotideacasestudy
AT vanackerf longtermdiseasecontrolofanonoperableneuroendocrinetumorofthelungwithlanreotideacasestudy
AT mattelaerc longtermdiseasecontrolofanonoperableneuroendocrinetumorofthelungwithlanreotideacasestudy
AT deruyterv longtermdiseasecontrolofanonoperableneuroendocrinetumorofthelungwithlanreotideacasestudy
AT schrijversd longtermdiseasecontrolofanonoperableneuroendocrinetumorofthelungwithlanreotideacasestudy

Ejemplares similares